Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Leslie Citrome, Christine Graham, Adam Simmons, Ying Jiang, Mark S Todtenkopf, Bernard Silverman, Lauren DiPetrillo, Hannah Cummings, Lei Sun & David McDonnell. (2021) An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder. Neuropsychiatric Disease and Treatment 17, pages 2885-2904.
Read now
Read now
Norio Sugawara, Norio Yasui-Furukori, Manabu Yamazaki, Kazutaka Shimoda, Takao Mori, Takuro Sugai, Hiroshi Matsuda, Yutaro Suzuki, Yoshitake Minami, Yuji Ozeki, Kurefu Okamoto, Toyoaki Sagae & Toshiyuki Someya. (2016) Attitudes toward metabolic adverse events among patients with schizophrenia in Japan. Neuropsychiatric Disease and Treatment 12, pages 427-436.
Read now
Read now
Elaine H Morrato. (2012) An update on lipid profile screening in second-generation antipsychotic users in the USA. Clinical Lipidology 7:5, pages 509-523.
Read now
Read now
Elaine Morrato & Daniel Hartung. (2010) Lipid profile screening in second-generation antipsychotic users: the gap between policy and practice. Clinical Lipidology 5:3, pages 299-303.
Read now
Read now
Garry Walter, Amy Delaroche, Nerissa Soh, Glenn Hunt, Michelle Cleary, Gin Malhi, Tim Lambert, Christoph Correll & Joseph Rey. (2008) Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. Australasian Psychiatry 16:4, pages 253-262.
Read now
Read now
Articles from other publishers (27)
Christoph U Correll, Evan Stein, Christine Graham, Lauren DiPetrillo, Sarah Akerman, Arielle D Stanford, Ying Jiang, Sergey Yagoda, David McDonnell & Craig Hopkinson. (2023) Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study. Schizophrenia Bulletin 49:2, pages 454-463.
Crossref
Crossref
Jonathan M. Meyer, Adam Simmons, Ying Jiang, Christine Graham, Sergey Yagoda & David McDonnell. (2022) Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients. CNS Spectrums, pages 1-4.
Crossref
Crossref
Frederico G. S. Toledo, William F. Martin, Linda Morrow, Carine Beysen, Daiva Bajorunas, Ying Jiang, Bernard L. Silverman, David McDonnell, Mark N. Namchuk, John W. Newcomer & Christine Graham. (2021) Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers. Neuropsychopharmacology 47:3, pages 696-703.
Crossref
Crossref
Debbie Cook. 2022. Bariatric Surgery in Clinical Practice. Bariatric Surgery in Clinical Practice
53
58
.
Sergey Yagoda, Christine Graham, Adam Simmons, Christina Arevalo, Ying Jiang & David McDonnell. (2020) Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. CNS Spectrums 26:4, pages 383-392.
Crossref
Crossref
Anastasiya Nestsiarovich, Berit Kerner, Aurélien J. Mazurie, Daniel C. Cannon, Nathaniel G. Hurwitz, Yiliang Zhu, Stuart J. Nelson, Tudor I. Oprea, Annette S. Crisanti, Mauricio Tohen, Douglas J. Perkins & Christophe G. Lambert. (2020) Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder. Psychoneuroendocrinology 112, pages 104511.
Crossref
Crossref
Debbie Cook. (2017) Obesity: New paradigms, interventions and treatments. Nurse Prescribing 15:7, pages 338-343.
Crossref
Crossref
Terence A. Ketter, Shefali Miller, Bernardo Dell’Osso & Po W. Wang. (2016) Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium. Journal of Affective Disorders 191, pages 256-273.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
597
660
.
Robert O. Cotes, Alex de Nesnera, Michael Kelly, Karen Orsini, Haiyi Xie, Greg McHugo, Stephen Bartels & Mary F. Brunette. (2015) Antipsychotic Cardiometabolic Side Effect Monitoring in a State Community Mental Health System. Community Mental Health Journal 51:6, pages 685-694.
Crossref
Crossref
F. Rouillon, E. Van Ganse, P. Vekhoff, R. Arnaud, L. Depret-Bixio & A. Dillenschneider. (2015) Niveau de vigilance des psychiatres pour les facteurs de risque cardiovasculaire chez les patients schizophrènes. L'Encéphale 41:1, pages 70-77.
Crossref
Crossref
Norio Sugawara, Norio Yasui-Furukori, Manabu Yamazaki, Kazutaka Shimoda, Takao Mori, Takuro Sugai, Yutaro Suzuki & Toshiyuki Someya. (2014) Psychiatrists' Attitudes toward Metabolic Adverse Events in Patients with Schizophrenia. PLoS ONE 9:1, pages e86826.
Crossref
Crossref
Whitney McKnight. (2011) Metabolic syndrome risk in patients prescribed atypical antipsychotics: As comorbidities multiply, the debate over monitoring responsibilities continues.. Psychiatric Annals 41:7, pages 347-349.
Crossref
Crossref
Karen E. Moeller, Sally K. Rigler, Angela Mayorga, Niaman Nazir & Theresa I. Shireman. (2011) Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance. Schizophrenia Research 126:1-3, pages 117-123.
Crossref
Crossref
Elaine H. Morrato, Benjamin G. Druss, Daniel M. Hartung, Robert J. Valuck, Deborah Thomas, Richard Allen, Elizabeth Campagna & John W. Newcomer. (2010) Small area variation and geographic and patient‐specific determinants of metabolic testing in antipsychotic users. Pharmacoepidemiology and Drug Safety 20:1, pages 66-75.
Crossref
Crossref
John W. Newcomer & Stefan Leucht. 2010. Schizophrenia. Schizophrenia
577
597
.
Roger S. McIntyre, Miriam Cohen, Jun Zhao, Larry Alphs, Thomas A. Macek & John Panagides. (2010) Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders 122:1-2, pages 27-38.
Crossref
Crossref
Elaine H. MorratoJohn W. NewcomerSiddhesh KamatOnur BaserJames HarnettBrian Cuffel. (2009) Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes. Diabetes Care 32:6, pages 1037-1042.
Crossref
Crossref
Keila Maria Mendes Ceres?r, Marcello ?vila Mascarenhas, Aida Santin & Fl?vio Kapczinski. (2009) Pilot-project of implantation of pharmaceutical care close to the program of bipolar mood disorder of the Hospital of Clinics of Porto Alegre. Brazilian Journal of Pharmaceutical Sciences 45:2, pages 249-256.
Crossref
Crossref
Elaine H. Morrato, Brian Cuffel, John W. Newcomer, Ilise Lombardo, Siddhesh Kamat & John Barron. (2009) Metabolic Risk Status and Second-Generation Antipsychotic Drug Selection. Journal of Clinical Psychopharmacology 29:1, pages 26-32.
Crossref
Crossref
Rif S. El-Mallakh. 2009.
25
32
.
Susan Simmons-AllingSandra Talley. (2008) Bipolar Disorder and Weight Gain: A Multifactorial Assessment. Journal of the American Psychiatric Nurses Association 13:6, pages 345-352.
Crossref
Crossref
Christoph U Correll, Anne M Frederickson, John M Kane & Peter Manu. (2008) Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disorders 10:7, pages 788-797.
Crossref
Crossref
Terence A. Ketter, John O. Brooks, Jennifer C. Hoblyn, Laurel M. Champion, Jennifer Y. Nam, Jenifer L. Culver, Wendy K. Marsh & Julie C. Bonner. (2008) Effectiveness of lamotrigine in bipolar disorder in a clinical setting. Journal of Psychiatric Research 43:1, pages 13-23.
Crossref
Crossref
Michael Bauer, Yves Lecrubier & Trisha Suppes. (2020) Conocimiento de los problemas metabólicos de los pacientes con trastorno bipolar: encuesta a psiquiatras europeos. European psychiatry (Ed. Española) 15:6, pages 273-282.
Crossref
Crossref
C. Torrent, B. Amann, J. Sánchez-Moreno, F. Colom, M. Reinares, M. Comes, A. R. Rosa, J. Scott & E. Vieta. (2008) Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatrica Scandinavica 118:1, pages 4-18.
Crossref
Crossref
Michael Bauer, Yves Lecrubier & Trisha Suppes. (2007) Awareness of Metabolic Concerns in Patients With Bipolar Disorder: A Survey of European Psychiatrists. European Psychiatry 23:3, pages 169-177.
Crossref
Crossref